Pacemaker & Leadless Implant Design Patent Landscape
The pacemaker and leadless implant design patent space is highly concentrated, with Pacesetter Inc alone accounting for well over a third of the top-ranked filers’ combined output; the field is in a declining phase on a multi-year basis, with annual volume easing back from its 2020 peak. A61N electrotherapy remains the dominant technology branch, while adjacent areas such as implant fixation, connector engineering, and wireless transmission remain comparatively sparse.
Pacesetter leads a tightly consolidated field of established cardiac device makers
Pacesetter Inc holds the top position with 473 patent records, followed by Medtronic Inc at 201 and Biotronik SE & Co KG at 171, making the top tier a small group of long-established cardiac rhythm management companies.
The top five filers collectively account for 61% of the hundred largest filers’ combined total, signaling a strongly consolidated competitive structure with a substantial gap between the first tier and the mid-tier challengers. Cardiac Pacemakers Inc (111 records) and MicroPort Sorin CRM Shanghai (55 records) round out the top five.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Pacesetter Inc | 473 | |
| 2 | Medtronic Inc | 201 | |
| 3 | BIOTRONIK SE & CO KG | 171 | |
| 4 | Cardiac Pacemakers Inc | 111 | |
| 5 | MicroPort Sorin CRM (Shanghai) Co Ltd | 55 | |
| 6 | St. Jude Medical AB | 51 | |
| 7 | Spectranetics Corp | 43 | |
| 8 | Intermedics Inc | 41 | |
| 9 | Nanostim Inc | 29 | |
| 10 | Telectronics | 20 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Pressure Products Medical Supplies Inc | 20 | |
| 12 | Siemens AG | 17 | |
| 13 | SigmaSense LLC | 17 | |
| 14 | TAU PNU Medical Co Ltd | 16 | |
| 15 | TAU Medical Inc | 14 | |
| 16 | Siemens Elema AB | 14 | |
| 17 | Kurth | 12 | |
| 18 | Eagle Point Medical LLC | 12 | |
| 19 | Leadmed Co Ltd | 12 | |
| 20 | Cardia Access Inc | 12 |
The leaders’ positions reflect decades of cumulative R&D investment in core electrotherapy and implant delivery engineering; new entrants face both a volume disadvantage and the need to differentiate in adjacent branches where incumbents are comparatively less active.
Filing counts for 2023–2025 are subject to publication lag and will rise as applications publish; the apparent recent decline partly reflects this effect. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Filing activity peaked in 2020 and has eased; electrotherapy dominates the technology mix
The annual filing trend chart and the technology composition chart together show a field that built up strongly through 2019–2020 and is now past its peak, with A61N electrotherapy representing the overwhelming majority of classified activity.
Annual filing trend
Filings climbed from 90 records in 2017 to a peak of 132 in 2020, then stepped back to the 77–116 range through 2022 before declining further in 2023 and 2024. The 2023–2025 bars should be treated as provisional given standard patent publication lag; the overall multi-year window shows a field that is past its 2020 peak.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61N (electrotherapy and radiation therapy) overwhelmingly dominates the technology mix, reflecting the core stimulation and sensing function of pacemakers. A61B (diagnosis and surgery) and A61M (devices for body fluids, including catheter-based delivery) are the next largest branches, pointing to procedural delivery and diagnostic adjuncts as secondary innovation areas. All other branches each represent a small fraction of classified records.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Leadless pacemaker and leadless pacemaker system
A leadless pacemaker and a leadless pacemaker system are disclosed. A housing of a pacemaker body of the leadless pacemaker is designed as a curved tubular structure and can be deployed at a site with a limited space in a curved configuration, which allows the curved surface structure to fit more closely myocardial or vascular tissue around the site… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Interactive programming and diagnostic system for … | 1,095 |
| 2 | System for detecting, diagnosing, and treating car… | 760 |
| 3 | Dual indifferent electrode pacemaker | 607 |
| 4 | Atrial rate based programmable pacemaker with auto… | 585 |
| 5 | Telescopic introducer with a compound curvature fo… | 524 |
| 6 | Method and system for recording, reporting, and di… | 499 |
| 7 | Leadless Cardiac Pacemaker with Secondary Fixation… | 459 |
| 8 | Leadless cardiac pacer | 455 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the competitive structure means for R&D investment decisions
Four structural observations — maturity, concentration, collaboration, and geography — shape the strategic options available to both incumbents and new entrants in pacemaker and leadless implant design.
Field is in decline, past its 2020 peak
The lifecycle stage is classified as Decline, with annual filings easing back from the 2020 peak of 132 records. The multi-year recent-window growth figure is negative at -29%. For R&D planners, this suggests the core electrotherapy design space is maturing; incremental improvements to established architectures face diminishing differentiation returns, and investment rationale increasingly shifts toward adjacent or enabling branches.
Lifecycle: DeclineTop five filers hold 61% of the leading cohort’s output
The top five applicants — Pacesetter Inc, Medtronic Inc, Biotronik SE & Co KG, Cardiac Pacemakers Inc, and MicroPort Sorin CRM Shanghai — collectively represent 61% of the hundred largest filers’ combined patent records. This degree of concentration in a declining field means that mid-tier players must carve out distinct technology niches rather than competing on volume. The gap between Pacesetter’s 473 records and the sixth-ranked filer (St. Jude Medical AB at 51) is substantial.
High concentrationCo-filing activity is minimal; only one pairing identified
Evidence shows a single documented co-applicant collaboration: St. Jude Medical AB and Siemens (four co-filed records). This very low level of inter-firm co-filing suggests that the dominant players have historically developed pacemaker and leadless implant IP independently. For a new entrant, the absence of an established collaborative ecosystem may represent both a barrier and an opportunity to form differentiated partnerships with academic or clinical institutions.
Low collaborationUnited States is the primary filing jurisdiction by a wide margin
The United States leads all jurisdictions with 807 patent records, followed by Europe (EPO) at 437 and WIPO (PCT) at 205. Australia (73), China (58), and Canada (42) are secondary markets. China’s relatively modest presence despite MicroPort Sorin CRM Shanghai ranking fifth in the applicant table suggests that Chinese filings may be underrepresented in this corpus or that Chinese market protection for legacy designs remains a gap for non-domestic players.
US-centricGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| St. Jude Medical AB | Siemens AG | 4 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Pacesetter and Medtronic lead on volume; Biotronik holds a stable challenger position
The applicant ranking is dominated by legacy cardiac rhythm management companies, with Pacesetter Inc’s volume reflecting its long history as both an independent innovator and a Siemens/St. Jude heritage entity. Momentum data show diverging recent trajectories among the top four.
Pacesetter Inc
Pacesetter Inc holds 473 patent records, the largest portfolio in this corpus by a factor of more than two over the next-ranked filer. Its technology emphasis is concentrated in A61N1 electrotherapy (361 records), with secondary activity in A61M25 catheter-based delivery (83 records) and A61B17 surgical instruments (80 records). Recent momentum shows a -40% decline versus the prior period, consistent with the field’s overall post-2020 easing.
473 patent recordsMedtronic Inc
Medtronic Inc ranks second with 201 patent records and is the only top-four applicant showing positive recent momentum at +100% versus the prior period — though this likely reflects recovery from a relatively low prior base rather than an absolute volume surge. Its technology focus is similarly anchored in A61N1 electrotherapy (196 records), with A61B5 diagnostic sensing (24 records) and A61M25 delivery devices (13 records) as secondary areas, indicating growing attention to sensing and diagnostic integration alongside core stimulation IP.
201 patent records| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Pacesetter Inc | 80 | ▼ -40% |
| Medtronic Inc | 28 | ▲ +100% |
| Biotronik SE & Co KG | 63 | ▬ -5% |
| MicroPort Sorin CRM (Shanghai) Co Ltd | 17 | ▼ -45% |
Under-served adjacent branches in implant fixation, connectors, and wireless transmission
Five IPC branches sit at the periphery of the corpus with low record counts and shares of 2% or below; while not all represent validated commercial opportunities, several have plausible technical relevance to the next generation of leadless and miniaturized cardiac implants.
H04B · Wireless transmission for leadless architectures
H04B (general transmission) accounts for only 38 records and a 1% share of classified activity, despite wireless telemetry being a functional requirement for leadless pacemakers. The former Nanostim portfolio — which specifically addresses transcutaneous communication — shows H04B13 as a notable focus, suggesting this branch is technically relevant but underexploited by the broader field. Engineers developing next-generation far-field or ultrasound-based cardiac communication may find comparative freedom to operate here, though a thorough freedom-to-operate analysis would be needed before drawing conclusions.
Search this in Eureka →A61F · Implant fixation and prosthetic anchoring
A61F (implants and prostheses) holds 46 records and a 2% share, despite fixation being a primary engineering challenge in leadless pacemaker deployment — secure anchoring without a lead is a known clinical concern. MicroPort Sorin CRM Shanghai is one of the few applicants with A61F2 entries in the applicant-tech data. The relative sparsity of this branch across the broader field suggests it remains an under-served area where differentiated fixation mechanism designs could be filed with less crowding than in the core A61N space.
Search this in Eureka →How leading applicants differ in their technology route emphasis
Route coverage across the main technology branches in the current evidence set.
| Player | A61N 1 · Electrotherapy & radiation therapy | A61B 5 · Diagnosis & surgery | A61B 17 · Diagnosis & surgery | A61M 25 · Devices for body fluids | H04B 13 · Transmission (general) |
|---|---|---|---|---|---|
| Pacesetter Inc | Strong · 361 | Emerging · 42 | Moderate · 80 | Moderate · 83 | Emerging · 19 |
| Medtronic Inc | Strong · 196 | Emerging · 24 | Emerging · 11 | Emerging · 13 | Absent |
| Biotronik SE & Co KG | Strong · 170 | Moderate · 36 | Emerging · 8 | Absent | Absent |
| Cardiac Pacemakers Inc | Strong · 111 | Moderate · 25 | Emerging · 15 | Absent | Absent |
| Nanostim Inc | Strong · 55 | Moderate · 19 | Absent | Moderate · 15 | Moderate · 16 |
| Spectranetics Corp | Strong · 43 | Absent | Strong · 42 | Absent | Absent |
| MicroPort Sorin CRM (Shanghai) Co Ltd | Strong · 55 | Absent | Absent | Absent | Absent |
Frequently asked questions
The corpus covers 824 patent families. The applicant ranking within that corpus is measured at the patent-record level, which can exceed the family total because a single family can designate multiple offices or carry multiple applicant names.
Pacesetter Inc leads with 473 patent records, more than double the next-ranked filer, Medtronic Inc, at 201 records. The top five applicants together represent 61% of the hundred largest filers’ combined total.
The field is classified as Decline. Annual filings peaked at 132 records in 2020 and have eased since. The recent-window growth figure is -29%. Counts for 2023–2025 remain provisional due to publication lag and will be revised upward as applications publish.
A61N (electrotherapy and radiation therapy) is by far the largest branch, reflecting the core stimulation function of pacemakers. A61B (diagnosis and surgery) and A61M (devices for body fluids, covering catheter delivery) are the next two largest, representing procedural delivery and diagnostic sensing.
The United States leads with 807 patent records, followed by Europe (EPO) at 437 and WIPO (PCT) at 205. Australia (73), China (58), and Canada (42) are the next largest jurisdictions.
Several branches have low record counts relative to the dominant A61N core: A61F (implant fixation and prostheses) and H01R (connectors and current collectors) each have 46 records at a 2% share, H04B (wireless transmission) has 38 records at 1%, and A61L (sterilisation) has 32 records at 1%. H04B is particularly notable given that wireless telemetry is a functional requirement for leadless devices.
Map your own pacemaker and leadless implant patent landscape
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.